Now Reading
Synovis Life Technologies Ranks 67th on Business Ethics' 100 Best Corporate Citizens List
Synovis Life Technologies Ranks 67th on Business Ethics' 100 Best Corporate Citizens List
Published 04-08-05
Submitted by Synovis Life Technologies
"We are very proud to be named one of the 100 Best Corporate Citizens," said Karen Larson, Synovis' president and chief executive officer. "Synovis has always placed a high priority on attracting and retaining a diverse workforce and fostering communications with our employees, shareholders, distributors and the general community; we are pleased to be recognized by Business Ethics for that commitment."
All companies in the Russell 1000 Index(R) are eligible for Business Ethics' 100 Best Corporate Citizens list. Each company is evaluated on performance in eight categories: governance, total return to shareholders, community, diversity, employees, environment, human rights and customers. Social performance data used to determine inclusion and rankings comes from Socrates, the comprehensive online social research database created by KLD Research & Analytics in Boston, Mass. A selection committee conducts additional research to ensure no social misconduct has occurred, primarily in accounting and governance issues.
About Synovis Life Technologies
Synovis Life Technologies, Inc., based in St. Paul, Minn., is a diversified medical device company engaged in developing, manufacturing and bringing to market medical devices for the surgical and interventional treatment of disease. For additional information on Synovis Life Technologies and its businesses, visit the company's Web site at www.synovislife.com.
Forward-looking statements contained in this press release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The statements can be identified by words such as "should", "could", "may", "will", "expect", "believe", "anticipate", "estimate", "continue", or other similar expressions. Certain important factors that could cause results to differ materially from those anticipated by the forward-looking statements made herein include the timing of product introductions, the number of certain surgical procedures performed, the level of orders from contract manufacturing customers, the results of the ongoing securities litigation, and the company's ability to effectively transition distribution in the territory affected by the previously announced distribution change, as well as the other factors found in the company's Annual Report on Form 10-K for the year ended October 31, 2004.
